Embecta: Stable Execution, GLP-1–Driven Growth Optionality, and Attractive Valuation Support Buy Rating and $25 Target

BTIG analyst Marie Thibault reiterated a Buy rating on Embecta Corporation on February 3 and set a price target of $25.00.

Marie Thibault has given his Buy rating due to a combination of factors that highlight both operational resilience and future growth potential. He notes that Embecta slightly exceeded expectations on both revenue and earnings, with strong performance in international markets helping to balance pressure in the U.S. While domestic pricing challenges are likely to push results toward the lower end of guidance, these concessions are expected to support more stable U.S. volumes over time. Thibault also views the company’s continued debt reduction, solid free cash flow generation, and progress on its brand transition as signs of disciplined financial management that support long-term value.

Thibault further emphasizes the importance of Embecta’s pipeline and partnerships, particularly its expanding role in the GLP-1 ecosystem. The company is collaborating with more than 30 pharmaceutical partners to bundle its pen needles with generic GLP-1 therapies, with early purchase commitments and planned launches across multiple international markets beginning in calendar 2026. Management’s outlook includes incremental contributions from new products and an expected recovery in China, aided by a lower-cost pen needle offering. Based on this combination of stable financial execution, emerging growth drivers, and what he views as an attractive valuation at roughly 8x his 12–24 month adjusted EPS projection, Thibault reaffirms a Buy rating and a $25 price target.

According to TipRanks, Thibault is an analyst with an average return of -8.8% and a 36.55% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Edwards Lifesciences, and Masimo.